BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shahid RA, Wang DQ, Fee BE, McCall SJ, Romac JM, Vigna SR, Liddle RA. Endogenous elevation of plasma cholecystokinin does not prevent gallstones. Eur J Clin Invest 2015;45:237-46. [PMID: 25641074 DOI: 10.1111/eci.12400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Buchanan KL, Rupprecht LE, Kaelberer MM, Sahasrabudhe A, Klein ME, Villalobos JA, Liu WW, Yang A, Gelman J, Park S, Anikeeva P, Bohórquez DV. The preference for sugar over sweetener depends on a gut sensor cell. Nat Neurosci 2022. [PMID: 35027761 DOI: 10.1038/s41593-021-00982-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
2 Parra-Landazury NM, Cordova-Gallardo J, Méndez-Sánchez N. Obesity and Gallstones. Visc Med 2021;37:394-402. [PMID: 34722722 DOI: 10.1159/000515545] [Reference Citation Analysis]
3 Gijbels E, Pieters A, De Muynck K, Vinken M, Devisscher L. Rodent models of cholestatic liver disease: A practical guide for translational research. Liver Int 2021;41:656-82. [PMID: 33486884 DOI: 10.1111/liv.14800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
4 Tharp KM, Khalifeh-Soltani A, Park HM, Yurek DA, Falcon A, Wong L, Feng R, Atabai K, Stahl A. Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis. Am J Physiol Gastrointest Liver Physiol 2016;310:G855-64. [PMID: 27033116 DOI: 10.1152/ajpgi.00316.2015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Wang HH, Portincasa P, Wang DQ. The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice. Eur J Clin Invest 2016;46:158-69. [PMID: 26683129 DOI: 10.1111/eci.12580] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 Castro-torres IG, Cárdenas-vázquez RDJ, Velázquez-gonzález C, Ventura-martínez R, De la O-arciniega M, Naranjo-rodríguez EB, Martínez-vázquez M. Future therapeutic targets for the treatment and prevention of cholesterol gallstones. European Journal of Pharmacology 2015;765:366-74. [DOI: 10.1016/j.ejphar.2015.08.045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]